Heart failure & cardiomyopathiesRandomised controlled trial
Oral Relaxin Receptor Agonist AZD5462 in Participants With Chronic Heart Failure: Primary Results From the LUMINARA Trial
- Randomised controlled trial
- international
- multicentre
- double-blind
- placebo-controlled
- dose-ranging
- 57 sites in 10 countries
Authors' conclusion
Among individuals with well-treated chronic HF, the addition of oral AZD5462 was well tolerated and demonstrated encouraging effects on cardiovascular hemodynamic measures across a wide range of left ventricular ejection fraction.
Study context
- Population
- Adults with chronic heart failure (HF) and LVEF ≤35% (cohort A) or 41% to 55% (cohort B)235 cohort A, 140 cohort B
- Comparison
- AZD5462 vs placebo
- Primary endpoint
- Change in end-systolic volume index (cohort A) and systemic vascular resistance index (cohort B)
- Follow-up
- 24 weeks
Primary result
As reported in the abstract
week 25
Placebo-adjusted change
−5.4 mL/m²
95% CI −10.9 to 0.1
P = 0.054
AZD5462 20 mg vs Placebo
placebo-adjusted change −5.4 mL/m² (95% CI −10.9 to 0.1); P = 0.054
- Cohort B: significant placebo-adjusted reductions in systemic vascular resistance index across all dose groups
- all P <0.05
Original publication
Oral Relaxin Receptor Agonist AZD5462 in Participants With Chronic Heart Failure: Primary Results From the LUMINARA Trial. Circulation. Published 30 August 2026. doi:10.1161/circulationaha.126.082763
Summarised from the published abstract; every number is checked against it